Pre-made Ganitumab benchmark antibody ( Whole mAb, anti-IGF1R therapeutic antibody, Anti-IGFR/CD221/IGFIR/JTK13 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-231

Pre-Made Ganitumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ganitumab a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-231-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Ganitumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody
INN Name Ganitumab
TargetIGF1R
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesAmgen;Millennium;NantWorks;National Cancer Institute (USA);Novartis;Takeda;Takeda Oncology;UCLAs Jonsson Comprehensive Cancer Center
Conditions Approvedna
Conditions ActiveEwing's sarcoma;Solid tumours;Rhabdomyosarcoma
Conditions DiscontinuedBreast cancer;Colorectal cancer;Sarcoma;Small cell lung cancer;Non-small cell lung cancer;Pancreatic cancer;Prostate cancer
Development Techna